
|Videos|September 10, 2021
Comparing suitable naïve versus pre-treated DME patients
Author(s)OT Staff Reports
Javier Zarranz-Ventura MD, PhD, FEBO, discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.
Advertisement
Javier Zarranz-Ventura MD, PhD, FEBO, a vitreoretinal consultant at
Institut Clínic de Oftalmologia (ICOF), Hospital Clínic de Barcelona andInstitut de Investigacions Biomediques August Pi i Sunyer (IDIBAPS), discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
CTS 2026: OTX-TKI demonstrates superiority over aflibercept in wet AMD—what the SOL-1 data mean for retina practice
2
StemSight gains patent for off-the-shelf limbal stem cell platform patent milestone for STE-101
3
Ranluspec FDA approval: Cyrus Karkaria, PhD, on biosimilar access, prefilled syringes, and long-term switching confidence
4
Geographic atrophy: When lesion borders cannot be graded
5




















